Designing chemical libraries directed to nuclear receptors

Nuclear Receptors as Drug Targets

Volumn 39, Issue , 2008, Pages 469-488

  Gregori Puigjané, Elisabet ^a   Mestres, Jordi ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Chemical libraries; Nuclear receptors

Indexed keywords

TRANSCRIPTION FACTORS;

CHEMICAL LIBRARIES; NUCLEAR RECEPTORS;

LIBRARIES;

EID: 84887228410     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623297.ch16     Document Type: Chapter

References (44)

1. Blaney, J.M. and Martin, E.J. (1997) Computational approaches for combinatorial library design and molecular diversity analysis. Current Opinion in Chemical Biology, 1, 54-59.
2. Lahana, R. (1999) How many leads from HTS? Drug Discovery Today, 4, 447-448.
3. Shuttleworth, S.J., Connors, R.V., Fu, J., Liu, J., Lizarzaburu, M.E., Qiu, W., Sharma, R., Wanska, M. and Zhang, A.J. (2005) Design and synthesis of protein superfamily-targeted chemical libraries for lead identification and optimization. Current Medicinal Chemistry, 12, 1239-1281.
4. Balakin, K.V., Tkachenko, S.E., Lang, S.A., Okun, I., Ivashchenko, A.A., Savchuk, N.P. (2002) Property-based design of GPCRtargeted library. Journal of Chemical Information and Computer Sciences, 42, 1332-1342.
5. Lowrie, J.F., Delisle, R.K., Hobbs, D.W. and Diller, D.J. (2004) The different strategies for designing GPCR and kinase targeted libraries. Combinatorial Chemistry & High Throughput Screening, 7, 495-510.
6. Lang, S.A., Kozyukov, A.V., Balakin, K.V., Skorenko, A.V., Ivashchenko, A.A. and Savchuk, N.P. (2002) Classification scheme for the design of serine protease targeted compound libraries. J Comput Aided Mol Design, 16, 803-807.
7. Stewart, E.L., Brown, P.J., Bentley, J.A. and Willson, T.M. (2004) Selection, application, and validation of a set of molecular descriptors for nuclear receptor ligands. Combinatorial Chemistry & High Throughput Screening, 7, 407-412.
8. Gronemeyer, H., Gustafsson, J.A. and Laudet, V. (2004) Principles for modulation of the nuclear receptor superfamily. Nature Rev Drug Discov, 3, 950-964.
9. Francis, G.A., Fayard, E., Picard, F. and Auwerx, J. (2006) Nuclear receptors and the control of metabolism. Annual Review of Physiology, 46, 1615-1622.
10. Shi, Y. (2007) Orphan nuclear receptors in drug discovery. Drug Discovery Today, 12, 440-445.
11. Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K.N., Reich, M., Hieronymus, H., Wei, G., Armstrong, S.A., Haggarty, S.J., Clemons, P.A., Carr, S.A., Lander, E.S. and Golub, T.R. (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science, 313, 1929-1935.
12. Bleicher, K.H., Böhm, H.-J., Müller, K. and Alanine, A.I. (2003) Hit and lead generation: beyond high-throughput screening. Nature Reviews Drug Discovery, 2, 369-378.
13. Mestres, J. (2004) Computational chemogenomics approaches to systematic knowledge-based drug discovery. Curr Opin Drug Discov Dev, 7, 304-313.
14. Savchuk, N.P., Balakin, K.V. and Tkachenko, S.E. (2004) Exploring the chemogenomic knowledge space with annotated chemical libraries. Current Opinion in Chemical Biology, 8, 412-417.
15. MDL Drug Data Report. MDL Information Systems Inc., San Ramon, CA. http://www.mdl.com.
16. Olah, M., Mracec, M., Ostopovici, L.,Rad, R., Bora, A., Hadaruga N., Olah, I., Banda, M., Simon, Z. and Oprea, T.I. (2004) WOMBAT:World ofMolecular Bioactivity, in Chemoinformatics in Drug Discovery (Ed. T.I. Oprea), Wiley-VCH, NewYork, pp. 223-239, http://www.sunsetmolecular.com.
17. AurSCOPE databases. Aureus Pharma, Paris, France. http://www.aureus-pharma.com.
18. MedChem and Target Inhibitor databases. GVK Biosciences, Hyderabad, India. http://www.gvkbio.com.
19. Cases, M., García-Serna, R., Hettne, K., Weeber, M., van der Lei, J., Boyer, S. and Mestres, J. (2005) Chemical and biological profiling of an annotated compound library directed to the nuclear receptor family. Current Topics in Medicinal Chemistry, 5, 763-772.
20. Nuclear Receptors Nomenclature Committee (1999) A unified nomenclature system for the nuclear receptor superfamily. Cell, 97, 161-163.
21. Sali, A., Glaeser, R., Earnest, T. and Baumeister, W. (2003) From words to literature in structural proteomics. Nature, 422, 216-225.
22. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N. and Bourne, P.E. (2000) The Protein Data Bank. Nucleic Acids Research, 28, 235-242.
23. Luisi, B.F., Xu, W.X., Otwinowski, Z., Freedman, L.P., Yamamoto, K.R. and Sigler, P.B. (1991) Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature, 352, 497-505.
24. Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H. and Moras, D. (1995) Crystal structure of the ligand binding domain of the human nuclear receptor RXR-α. Nature, 375, 377-382.
25. García-Serna, R., Opatowski, L. and Mestres, J. (2006) FCP: functional coverage of the proteome by structures. Bioinformatics, 22, 1792-1793.
26. Mestres, J. (2005) Representativity of target families in the Protein Data Bank: impact for family-directed structure-based drug discovery. Drug Discovery Today, 10, 1629-1637.
27. Ekins, S., Mestres, J. and Testa, B. (2007) In silico pharmacology for drug discovery:methods for virtual ligand screening and profiling. British Journal of Pharmacology, 152, 9-20.
28. Zhang, Q. and Muegge, I. (2006) Scaffold hopping through virtual screening using 2D and 3D similarity descriptors:ranking, voting, and consensus scoring. Journal of Medicinal Chemistry, 49, 1536-1548.
29. Keiser, M.J., Roth, B.L., Armbruster, B.N., Ernsberger, P., Irwin, J.J. and Shoichet, B.K. (2007) Relating protein pharmacology by ligand chemistry. Nature Biotech, 25, 197-206.
30. Gregori-Puigjané, E. and Mestres, J. (2006) SHED: Shannon entropy descriptors from topological feature distributions. Journal of Chemical Information and Modeling, 46, 1615-1622.
31. Mestres, J., Martín-Couce, L., Gregori-Puigjané, E., Cases, M. and Boyer, S. (2006) Ligand-based approach to in silico pharmacology: nuclear receptor profiling. Journal of Chemical Information and Modeling, 46, 2725-2736.
32. McGovern, S.L. and Shoichet, B.K. (2003) Information decay in molecular docking screens against holo, apo and modeled conformations of enzymes. Journal of Medicinal Chemistry, 46, 2895-2907.
33. Gohlke, H. and Klebe, G. (2002) Approaches to the description and prediction of the binding affinity of smallmolecule ligands to macromolecular receptors. Angewand te Chemie International Edition, 41, 2644-2676.
34. Fradera, X. and Mestres, J. (2004) Guided docking approaches to structure-based design and screening. Current Topics in Medicinal Chemistry, 4, 687-700.
35. Schapira, M., Abagyan, R. and Totrov, M. (2003) Nuclear hormona receptor targeted virtual screening. Journal of Medicinal Chemistry, 46, 3045-3059.
36. Vieth, M. and Sutherland, J.J. (2006) Dependence of molecular properties on proteomic family for marketed oral drugs. Journal of Medicinal Chemistry, 49, 3451-3453.
37. Morphy, R. (2006) The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. Journal of Medicinal Chemistry, 49, 2969-2978.
38. Patchett, A. and Nargund, R.P. (2000) Privileged structures: an update. Annual Reports in Medicinal Chemistry, 35, 289-298.
39. Schnur, D.M., Hermsmeier, M.A. and Tebben, A.J. (2006) Are target-familyprivileged substructures truly privileged? Journal of Medicinal Chemistry, 49, 2000-2009.
40. Bemis, G.W. and Murcko, M.A. (1996) The properties of known drugs. I. Molecular frameworks. Journal of Medicinal Chemistry, 39, 2887-2893.
41. Hajduk, P.J., Bures, M., Praestgaard, J. and Fesik, S.W. (2000) Privileged molecules for protein binding identified from NMR-based screening. Journal of Medicinal Chemistry, 43, 3443-3447.
42. Hambly, K., Danzer, J., Muskal, S. and Debe, D.A. (2006) Interrogating the druggable genome with structural informatics. Molecular Diversity, 10, 273-281.
43. Erbe, D.V., Gartrell, K., Zhang, Y.-L., Suri, V., Kirincich, S.J., Will, S., Perreault, M., Wang, S. and Tobin, J.F. (2006) Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists. Vascular Pharmacology, 45, 154-162.
44. Hettne, K., Cases, M., Boyer, S. and Mestres, J. (2007) Connecting small molecules to nuclear receptor pathways. Current Topics in Medicinal Chemistry, 7, 1530-1536.